Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DURECT CORPORATION

(DRRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

DURECT : Earnings Flash (DRRX) DURECT CORPORATION Reports Q2 Revenue $2.3M, vs. Street Est of $3.65M

07/29/2021 | 04:16pm EDT


© MT Newswires 2021
All news about DURECT CORPORATION
10/07DURECT CORPORATION : Fireside Chat at the H.C. Wainwright 5th Annual NASH Investor Confere..
PR
09/23DURECT CORPORATION : Fireside Chat at the Cantor Fitzgerald Global Healthcare Conference 2..
PR
09/15DURECT CORPORATION : Fireside Chat at Oppenheimer's Fall Healthcare Life Sciences & MedTec..
PR
09/07DURECT CORPORATION : Fireside Chat at the H.C. Wainwright Annual Global Investment Confere..
PR
08/02DURECT : Chardan Suspends Coverage on Durect at Buy Rating With $8 Price Target
MT
08/02DURECT : Files for Up to $250 Million Mixed-Securities Shelf
MT
07/30DURECT : Management's Discussion and Analysis of Financial Condition and Results of Operat..
AQ
07/29DURECT : Q2 Earnings Snapshot
AQ
07/29DURECT CORPORATION ANNOUNCES SECOND : 30 p.m. ET (Form 8-K)
PU
07/29DURECT CORP : Results of Operations and Financial Condition, Financial Statements and Exhi..
AQ
More news
Analyst Recommendations on DURECT CORPORATION
More recommendations
Financials (USD)
Sales 2021 8,56 M - -
Net income 2021 -40,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,27x
Yield 2021 -
Capitalization 262 M 262 M -
Capi. / Sales 2021 30,6x
Capi. / Sales 2022 17,7x
Nbr of Employees 79
Free-Float 98,6%
Chart DURECT CORPORATION
Duration : Period :
DURECT Corporation Technical Analysis Chart | DRRX | US2666051048 | MarketScreener
Technical analysis trends DURECT CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 1,15 $
Average target price 6,33 $
Spread / Average Target 451%
EPS Revisions
Managers and Directors
James E. Brown President, Chief Executive Officer & Director
Michael H. Arenberg Chief Financial Officer & Secretary
David R. Hoffmann Chairman
Wei Qi Lin Executive Vice President-Research & Development
David J. Ellis Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
DURECT CORPORATION-44.44%262
GILEAD SCIENCES, INC.14.76%83 830
BIONTECH SE230.50%65 071
WUXI APPTEC CO., LTD.25.14%64 894
REGENERON PHARMACEUTICALS16.48%58 504
VERTEX PHARMACEUTICALS-21.52%48 121